

Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with rivaroxaban

Kirchhof, Paulus; Haas, Sylvia; Amarenco, Pierre; Hess, Susanne; Lambelet, Marc; Van Eickels, Martin; Turpie, Alexander G G; Camm, A John

DOI:

[10.1161/JAHA.118.009530](https://doi.org/10.1161/JAHA.118.009530)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Kirchhof, P, Haas, S, Amarenco, P, Hess, S, Lambelet, M, Van Eickels, M, Turpie, AGG & Camm, AJ 2020, 'Impact of modifiable bleeding risk factors on major bleeding in patients with atrial fibrillation anticoagulated with rivaroxaban', *Journal of the American Heart Association*, vol. 9, no. 5, e009530, pp. e009530. <https://doi.org/10.1161/JAHA.118.009530>

[Link to publication on Research at Birmingham portal](#)

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban

Paulus Kirchhof, MD; Sylvia Haas, MD; Pierre Amarenco, MD, PhD; Susanne Hess, MD; Marc Lambelet, Dipl-Math; Martin van Eickels, MD; Alexander G. G. Turpie, MD; A. John Camm, MD; on behalf of the XANTUS Investigators*

Background—Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation receiving rivaroxaban and estimated the impact of risk factor modification on major bleeding events.

Methods and Results—Modifiable and nonmodifiable risk factors associated with major bleeding events were identified from the XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) prospective registry data set (6784 rivaroxaban-treated patients). Parameters showing univariate association with bleeding were used to construct a multivariable model identifying independent risk factors. Modeling was used to estimate attributed weights to risk factors. Heavy alcohol use (hazard ratio [HR] =2.37; 95% CI 1.24–4.53); uncontrolled hypertension (HR after parameter-wise shrinkage=1.79; 95% CI 1.05–3.05); and concomitant treatment with antiplatelets, nonsteroidal anti-inflammatory drugs, or paracetamol (HR=1.80; 95% CI 1.24–2.61) were identified as modifiable, independent bleeding risk factors. Increasing age (HR=1.25 [per 5-year increment]; 95% CI 1.12–1.38); heart failure (HR=1.97; 95% CI 1.36–2.86); and vascular disease (HR=1.91; 95% CI 1.32–2.77) were identified as nonmodifiable bleeding risk factors. Overall, 128 (1.9%) patients experienced major bleeding events; of these, 11% had no identified bleeding risk factors, 50% had nonmodifiable bleeding risk factors only, and 39% had modifiable bleeding risk factors (with or without nonmodifiable risk factors). The presence of 1 modifiable bleeding risk factor doubled the risk of major bleeding.

Conclusions—Elimination of modifiable bleeding risk factors is a potentially effective strategy to reduce bleeding risk in atrial fibrillation patients receiving rivaroxaban.

Clinical Trial Registration—URL: <http://www.clinicaltrials.gov>. Unique identifier: NCT01606995. (*J Am Heart Assoc.* 2020;9:e009530. DOI: 10.1161/JAHA.118.009530.)

Key Words: anticoagulation • independent predictor • major bleeding • modeling study • modifiable risk factor

Oral anticoagulation with vitamin K antagonists or non-vitamin K antagonist oral anticoagulants (NOACs)¹ prevents stroke and prolongs life in patients with atrial fibrillation (AF).^{1–4} Although most patients benefit from oral anticoagulation, all anticoagulants increase the risk of major bleeding, including fatal events. Several bleeding risk factors (eg, higher age or prior stroke)^{5–9} cannot be modified and also

identify patients with AF at high risk of stroke. Others, such as concomitant therapy with antiplatelet agents or uncontrolled hypertension, are modifiable and offer opportunities to reduce bleeding risk.³ Although recent guidelines on the management of AF recommend treating modifiable bleeding risk factors,³ the impact of such factors on outcomes in anticoagulated patients with AF has never been quantified. Furthermore,

From the Institute of Cardiovascular Sciences, University of Birmingham and UHB and Sandwell & West Birmingham Hospitals NHS Trusts, Birmingham, United Kingdom (P.K.); University Heart and Vascular Center Hamburg, Hamburg, Germany (P.K.); Formerly Technical University of Munich, Munich, Germany (S. Haas); Department of Neurology and Stroke Centre, Paris-Diderot-Sorbonne University, Paris, France (P.A.); Medical Affairs, Bayer AG, Berlin, Germany (S. Hess, M.v.E.); Chrestos Concept GmbH & Co KG, Essen, Germany (S. Hess, M.L.); Department of Medicine, McMaster University, Hamilton, Ontario, Canada (A.G.G.T.); Cardiovascular and Cell Sciences Research Institute and Cardiology Clinical Academic Group, St George's, University of London, London, United Kingdom (A.J.C.).

Accompanying Appendix S1, Tables S1 through S13, and Figures S1 through S3 are available at <https://www.ahajournals.org/doi/suppl/10.1161/JAHA.118.009530>

*The members of the XANTUS Investigators are given in Appendix S1.

Correspondence to: Paulus Kirchhof, MD, Institute of Cardiovascular Sciences, University of Birmingham, IBR 136, Birmingham B15 2TT, United Kingdom. E-mail: p.kirchhof@bham.ac.uk

Received August 3, 2018; accepted October 4, 2019.

© 2020 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Clinical Perspective

What Is New?

- In patients with atrial fibrillation treated with rivaroxaban, heavy alcohol use, uncontrolled hypertension, and concomitant treatment with antiplatelets, nonsteroidal anti-inflammatory drugs, or paracetamol were identified as modifiable, independent bleeding risk factors; increasing age, heart failure, and vascular disease were identified as nonmodifiable bleeding risk factors.
- Thirty-nine percent of patients who experienced major bleeding events had at least 1 modifiable bleeding risk factor (most of whom also had additional nonmodifiable risk factors).
- The presence of 1 or more of the 3 independent modifiable bleeding risk factors identified in this analysis was associated with a 2-fold increase in the risk of major bleeding.

What Are the Clinical Implications?

- Eliminating or reducing modifiable bleeding risk factors (eg, heavy alcohol use, uncontrolled hypertension, and concomitant therapy with antiplatelets, nonsteroidal anti-inflammatory drugs, or paracetamol) in the context of integrated atrial fibrillation care may be an effective strategy to reduce the risk of bleeding in anticoagulated patients with atrial fibrillation.

bleeding risk factors in patients treated with NOACs may be different from bleeding risk factors in patients treated with vitamin K antagonists. In this analysis, modifiable and nonmodifiable risk factors of major bleeding were identified in an unselected cohort of AF patients treated with the NOAC rivaroxaban, and the potential maximum benefits of reducing modifiable risk factors were modeled.

Methods

The authors declare that all supporting data are available within the article and its online supplementary files.

Patients and Outcome Definitions

The XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) data set was analyzed; XANTUS, a safety study mandated by the European Medicines Agency, was a real-world, prospective, observational registry that enrolled unselected adult patients (aged ≥ 18 years) with AF who had been newly prescribed rivaroxaban for stroke/systemic embolism prevention in routine clinical practice.¹⁰ Patients who did not provide informed consent were ineligible and contraindications were considered according to the product

label. Dose and duration of rivaroxaban therapy were solely at the discretion of the prescribing physician. The study received all appropriate approval by Health Authorities, independent Ethics Committees, and Independent Review Boards. All participants gave written informed consent to participate in the study.¹⁰ All bleeding events reported by the investigators were analyzed and adjudicated centrally as major or nonmajor based on predefined criteria in accordance with the International Society on Thrombosis and Haemostasis definition of major bleeding. An event was considered treatment emergent if it started on or after the day of the first dose of rivaroxaban and up to 2 days after the last dose. Only treatment-emergent major bleeding events were used in the analysis because nonmajor bleeding events may be less accurately recorded in an observational setting, and are less likely to be as clinically relevant; bleeding events occurring after discontinuation of rivaroxaban are unlikely to be treatment related. Patient characteristics, including comorbidities and potential risk factors for bleeding events, were recorded as assessed by the treating physician at the initial screening visit before enrollment in the study, except for creatinine clearance (CrCl) and weight (used for body mass index calculation), which were first available values, recorded at any time during the study. Definitions for hypertension, heart failure, and vascular disease are summarized in Table S1. Concomitant medications taken at the time of commencing rivaroxaban therapy and initiated any time after the start of rivaroxaban therapy were recorded during the initial and follow-up visits, respectively. After the initial screening visit, patients were followed up at ≈ 3 -month intervals for up to 1 year or until 30 days after permanent discontinuation (if < 1 year) of rivaroxaban treatment.

Statistical Methods

All analyses were based on the safety analysis set, which included all patients exposed to at least 1 dose of rivaroxaban during the observation period. Potential risk factors were explored using separate univariate Cox proportional hazard models, which included all patients with available data for each risk factor assessed. The univariate analyses included both continuous and categorical versions of a variable where applicable. Risk factors with a univariate $P < 0.10$ were considered as candidates. In case of high correlation among factors (assessed using Kendall's tau), candidates were removed based on medical judgment. Additional risk factors with $P \geq 0.10$ were chosen as candidates for the multivariable model selection procedure for medical reasons. Medical judgment was also used to decide whether continuously measured variables were included as continuous (ie, age) or categorical variables (ie, first available CrCl < 50 mL/min versus ≥ 50 mL/min; first available weight > 60 kg versus ≤ 60 kg) in the multivariable model. The risk factors selected

after the univariate analyses (Table S2) were included into a multivariable Cox regression model. A backward elimination with a significance level of $P=0.10$ for keeping variables in the model was performed to identify a model with multiple risk factors. Patients with missing values were not included (ie, a multiple imputation model was not performed). The proportional hazards assumption of the Cox model and linearity of age were assessed graphically (Figures S1 and S2). A sensitivity analysis was carried out in which missing values for CrCl were imputed. The model fit of the final multivariable model was assessed visually using a calibration plot (Figure S3),¹¹ and model discrimination was assessed using Harrell's C statistic (Table S3).¹¹ An internal validation of the model was performed (ie, the C-statistic corrected for optimism was calculated via the bootstrap technique [200 samples])¹¹; parameter estimates were adjusted with parameter-wise shrinkage factors, and corresponding hazard ratios (HRs) were determined.¹²

The identified risk factors in the final multivariable model were divided into modifiable and nonmodifiable, and the impact of the modifiable risk factors was assessed by comparing the model-predicted probabilities of major bleeding over time for selected types of patients by showing modeled Kaplan–Meier curves for patients with or without modifiable risk factors and by computing partial population-attributable risks. The partial population-attributable risks give the maximum proportion of events that could theoretically be prevented if a specific risk factor (and any associated pathologies) were completely eliminated/reversed. It is applicable in cases where there is more than 1 risk factor of interest and when the set of risk factors includes both modifiable and nonmodifiable risk factors.¹³

Paulus Kirchhof and the co-authors had access to all the data in the study. Paulus Kirchhof takes responsibility for its integrity and data analysis. The study sponsor oversaw data management and statistical analyses to adhere to Good Clinical Practice standards, while the lead statistician oversaw programming and validation of the statistical analyses.

Results

Treatment-emergent major bleeding events occurred in 128 patients over a mean treatment duration of 329 days (2.1 events per 100 patient-years). Compared with patients without major bleeding events, those with major bleeding events were older; more of them had heart failure and vascular heart disease; and they were more often treated with concomitant antiplatelets, nonsteroidal anti-inflammatory drugs (NSAIDs), or paracetamol (Table 1). Overall, 118 patients (1.9 events per 100 patient-years) died and, of these, 12 (0.2 per 100 patient-years) died of a bleeding event (Table 2). Baseline characteristics of patients who had major

bleeding events or died, compared with patients not experiencing these outcomes, are included in Table S4. The mean treatment duration (follow-up) (\pm SD) was 329 (\pm 115) days, with a median treatment duration (interquartile range) of 366 (343–379) days. In total, 4223/6784 (62.2%) patients were treated for 1 year.

The multivariable analysis included 4127 patients with all data for candidate risk factors available (Figure 1). Compared with patients excluded from the model, patients who were included had a similar mean age and a similar proportion of them were elderly (aged ≥ 75 years old); however, they were more likely to have heart failure or vascular disease and, as expected based on rivaroxaban dosing recommendations being dependent on renal function, a higher proportion received an initial daily dose of 15 mg (Table S5). Differences in baseline characteristics between the 105 patients with major bleeding and the 4022 patients without major bleeding, who were included in the model population, were similar to the differences between patients with and without major bleeding in the overall XANTUS population (Table S6). The results of the multivariate analysis, which included all factors that showed a tendency to be different in the univariate comparison and those included in the model that were based on medical judgment (Table S2), identified 6 independent factors associated with major bleeding on treatment with rivaroxaban (Figure 2):

1. Concomitant antiplatelet, NSAID, or paracetamol treatment at any time during the study (HR=1.80; 95% CI 1.24–2.61).
2. Uncontrolled hypertension, defined as blood pressure $>160/90$ mm Hg at baseline (HR=1.79; 95% CI 1.05–3.05).
3. Heavy (>80 g alcohol/d; HR=2.37; 95% CI 1.24–4.53; $P=0.009$) but not moderate (40–80 g alcohol/d; HR=0.96; 95% CI 0.62–1.46; $P=0.819$) alcohol use at baseline.
4. Increasing age at baseline (HR after parameter-wise shrinkage=1.25 [per 5-year increase]; 95% CI 1.12–1.38).
5. Heart failure at baseline (HR=1.97; 95% CI 1.36–2.86).
6. Vascular disease at baseline (HR=1.91; 95% CI 1.32–2.77).

These risk factors were confirmed in a sensitivity analysis using major bleeding or death as outcome parameters (Table S7), with the exception of heavy alcohol use (defined in Table S8) and uncontrolled hypertension (defined in Table S1). In the univariate analyses, HRs for concomitant antiplatelets, NSAIDs, and paracetamol were 1.69 (95% CI 1.13–2.55; $P=0.012$), 1.73 (95% CI 0.76–3.92; $P=0.191$), and 2.64 (95% CI 1.34–5.19; $P=0.005$), respectively (Table S9). An additional sensitivity analysis, which included 87% of the overall XANTUS population by imputing missing CrCl values, showed consistent outcomes in the multivariable model (Table S10).

Table 1. Baseline Demographics and Clinical Characteristics of Patients With and Without Treatment-Emergent Major Bleeding Events in XANTUS

	All Patients (N=6784)	Patients With Major Bleeding (n=128)	Patients Without Major Bleeding (n=6656)	P Value
Age, y, mean±SD	71.5±9.95	75.9±9.35	71.4±9.94	<0.001
<75 y, n (%)	3975 (58.6)	52 (40.6)	3923 (58.9)	<0.001
≥75 y, n (%)	2809 (41.4)	76 (59.4)	2733 (41.1)	<0.001
Male, n (%)	4016 (59.2)	81 (63.3)	3935 (59.1)	0.3457
Body mass index, kg/m ² , mean±SD	28.3±4.98	28.1±5.25	28.3±4.98	0.5769
First available creatinine clearance, n (%)	0.0246
<80 mL/min	2961 (43.6)	87 (68.0)	2874 (43.2)	...
≥80 mL/min	1491 (22.0)	27 (21.1)	1464 (22.0)	...
Missing	2332 (34.4)	14 (10.9)	2318 (34.8)	...
Hepatic insufficiency, n (%)*	137 (2.0)	6 (4.7)	131 (2.0)	0.0303
Rivaroxaban dose (first documented), n (%)	0.0004
15 mg	1410 (20.8)	39 (30.5)	1371 (20.6)	...
20 mg	5336 (78.7)	86 (67.2)	5250 (78.9)	...
Other/missing	38 (0.6)	3 (2.3)	35 (0.5)	...
Concomitant ASA or NSAID, n (%)	1118 (16.5)	33 (25.8)	1085 (16.3)	0.0042
Concomitant dual antiplatelets, n (%)	105 (1.5)	5 (3.9)	100 (1.5)	0.0291
Concomitant antiplatelet, NSAID, or paracetamol, n (%)	1363 (20.1)	41 (32.0)	1322 (19.9)	0.0007
Concomitant CYP3A4 or P-gp inhibitors, n (%) [†]	1313 (19.4)	40 (31.3)	1273 (19.1)	0.0006
Concomitant paracetamol, n (%)	191 (2.8)	9 (7.0)	182 (2.7)	0.0036
Active cancer, n (%)	105 (1.5)	3 (2.3)	102 (1.5)	0.4614
Prior bleeding, n (%)	49 (0.7)	1 (0.8)	48 (0.7)	0.9366
Ulcerative gastrointestinal disease, n (%)	27 (0.4)	1 (0.8)	26 (0.4)	0.4869
Uncontrolled hypertension, n (%)	275 (4.1)	8 (6.3)	267 (4.0)	0.2034
Prior stroke, n (%)	935 (13.8)	22 (17.2)	913 (13.7)	0.2598
Prior MI, n (%)	688 (10.1)	19 (14.8)	669 (10.1)	0.0752
Heart failure at baseline, n (%)	1265 (18.6)	45 (35.2)	1220 (18.3)	<0.0001
Platelet count <80 000, n (%)	39 (0.6)	2 (1.6)	37 (0.6)	0.3577
Diabetes mellitus, n (%)	1333 (19.6)	31 (24.2)	1302 (19.6)	0.1890
Vascular disease, n (%)	1685 (24.8)	55 (43.0)	1630 (24.5)	<0.0001
Heavy alcohol use, n (%)	54 (0.8)	3 (2.3)	51 (0.8)	0.0791
Anemia/reduced hemoglobin, n (%)	203 (3.0)	6 (4.7)	197 (3.0)	0.2558
Known coagulopathy, n (%)	19 (0.3)	1 (0.8)	18 (0.3)	0.2787
Bridging therapy during interruptions, n (%)	100 (1.5)	11 (8.6)	89 (1.3)	<0.0001

The baseline demographics and clinical characteristics from patients in the XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) study were stratified according to the presence or absence of major bleeding. ASA indicates acetylsalicylic acid; CYP3A4, cytochrome P450 3A4; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein.

*Defined as "abnormal liver function" by the study investigator.

[†]Strong, moderate, and weak inhibitors were included.

In total, 1634 patients (24%) had at least 1 modifiable bleeding risk factor: 541 had modifiable risk factors only and 1093 patients had both modifiable and nonmodifiable risk factors. Incidence rates of major bleeding (events per 100

patient-years [95% CI]) increased with the number of modifiable risk factors (0, 1, or 2 risk factors, respectively) from 1.66 (1.31–2.07, no risk factor) to 3.56 (2.62–4.72, 1 risk factor) and 4.16 (0.50–15.02, 2 risk factors) (Table 3).

Table 2. Characteristics of Patients Who Died of a Bleeding Event in XANTUS

Patient	Event	Concomitant Cardiovascular Conditions
1: 73 y old	ICH, 7 mo after rivaroxaban start (15 mg od)	Hypertension
2: 85 y old	ICH, 14 d after rivaroxaban start (15 mg od)	Prior TIA, CHF, vascular disease, hypertension
3: 74 y old	ICH, 6 mo after rivaroxaban start (15 mg od)	Vascular disease, diabetes mellitus, hypertension
4: 80 y old	ICH, 4 mo after rivaroxaban start (20 mg od)	CHF
5: 60 y old	ICH, 9 mo after rivaroxaban start (20 mg od)	Obesity, CHF, hypertension
6: 63 y old	ICH, 8 mo after rivaroxaban start (20 mg od)	Hypertension
7: 66 y old	ICH, 10 mo after rivaroxaban start (20 mg od)	CHF, vascular disease, hypertension
8: 70 y old	Extracranial bleeding, 3 mo after rivaroxaban start (20 mg od)	CHF, hypertension
9: 76 y old	GI bleeding, 11 mo after rivaroxaban start (20 mg od)	Anemia and prior hemorrhoidal bleeding, CHF, vascular disease, diabetes mellitus, obesity
10: 56 y old	Rectal bleeding, 4 mo after rivaroxaban start (20 mg od)	Prior systemic embolism, CHF, hypertension, obesity
11: 74 y old	Intra-alveolar hemorrhage, 6 wks after rivaroxaban start (15 mg od)	Hypertension
12: 87 y old	Aortic aneurysm rupture, 10 mo after rivaroxaban start (15 mg od)	CHF, vascular disease, hypertension

All patients had atrial fibrillation and were treated with rivaroxaban. CHF indicates congestive heart failure; GI, gastrointestinal; ICH, intracranial hemorrhage; od, once daily; TIA, transient ischemic attack; XANTUS, Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation.

Incidences of major bleeding or death also increased with the number of modifiable risk factors (Table S11). Importantly, 50/128 (39%) patients who had a bleeding event had at least 1 modifiable bleeding risk factor (most of whom also had

additional nonmodifiable risk factors) (Figure 3), suggesting that a substantial proportion of bleeding events could be attributable to modifiable bleeding risk factors. An additional analysis testing for interactions between the modifiable risk




Figure 1. Flow chart of patients in this analysis (STROBE format). *Patients can have missing data in more than 1 candidate risk factor. †Patients who died (treatment-emergent) with bleeding as cause of death based on model population. ‡Patients who died (treatment-emergent) excluding bleeding as cause of death based on model population. CrCl indicates creatinine clearance.




Figure 2. Risk factors associated with major bleeding events in XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation). Forest plot showing all factors associated with major bleeding events in the XANTUS population after parameter-wise shrinkage. Alcohol consumption was defined as: abstinent (0 g alcohol/d); mild (<40 g alcohol/d); moderate (40–80 g alcohol/d); or heavy (>80 g alcohol/d). AP indicates antiplatelet; NSAID, nonsteroidal anti-inflammatory drug.

factors and age (as a continuous risk factor) showed no significant interaction. *P* values for interactions between age and alcohol consumption; concomitant antiplatelet, NSAIDs, or paracetamol use; and uncontrolled hypertension were 0.746, 0.997, and 0.171, respectively (Table S12).

Patients without modifiable bleeding risk factors had a bleeding risk of 1.7% at day 360, increasing to 3.3% in patients with at least 1 modifiable bleeding risk factor (Figure 4A). The discrimination power of modifiable bleeding risk factors was similar to the discriminatory power of the published HAS-BLED and ORBIT bleeding risk scores (Table S13): major bleeding incidence rates (events per 100 patient-years [95% CI]) for patients with low, medium, and high HAS-BLED bleeding risk (score=0, 1–2, and ≥ 3 , respectively) were 0.36 (0.01–2.03), 1.89 (1.49–2.35), and 2.88 (2.12–3.82), respectively. Bleeding rates for low, medium, and high ORBIT score (0–2, 3, and 4–7, respectively) were 2.61 (1.72–3.80), 5.89 (3.13–10.07), and 5.54 (2.76–9.91), respectively.

The increased bleeding risk was confirmed in a modeling analysis estimating the impact of modifiable bleeding risk factors in patients with an average profile of nonmodifiable risk factors. The probability of major bleeding events rose from 2% at day 360 in patients without modifiable bleeding risk factors to 16% in patients with all 3 modifiable risk factors (Figure 4B). The partial population-attributable risk analysis showed that eliminating all modifiable bleeding risk factors would reduce the bleeding risk by up to 16%; values attributable to bleeding risk for each modifiable risk factor can be found in Table 4.

Discussion

Main Findings

This analysis quantified the impact of modifiable and nonmodifiable bleeding risk factors in an unselected cohort

Table 3. Major Bleeding in the XANTUS Population Stratified by Number of Modifiable Bleeding Risk Factors

Number of Modifiable Risk Factors	Overall, n (%)	Patients With Major Bleeding*, n (%)	Incidence Proportion, % (95% CI)	Incidence Rate Events Per 100 Years (95% CI)
0	5150 (75.9)	78 (1.5)	1.51 (1.20–1.89)	1.66 (1.31–2.07)
1	1577 (23.2)	48 (3.0)	3.04 (2.25–4.02)	3.56 (2.62–4.72)
$\geq 2^{\dagger}$	57 (0.8)	2 (3.5)	3.51 (0.43–12.11)	4.15 (0.50–14.98)

Number of patients and major bleeding events from the XANTUS (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation) study were stratified according to number of modifiable risk factors.

*Treatment emergent adjudicated.

[†]Only 1 patient had 3 modifiable bleeding risk factors and did not experience a bleeding event.




Figure 3. Patient risk profiles. Donut chart showing study population (outer ring) and patients who experienced a major bleeding event (inner ring) according to the presence of bleeding risk factors, split into modifiable and nonmodifiable risk factors. Age ≥ 75 years was used as a cut-off point for age to qualify as a nonmodifiable risk factor.

of patients with AF treated with rivaroxaban in routine clinical practice. Iterative analyses identified 3 modifiable and 3 nonmodifiable risk factors associated with bleeding in patients with AF receiving rivaroxaban. Almost 40% of major bleeding events occurred in patients with at least 1 modifiable risk factor. Elimination of modifiable bleeding risk factors (eg, heavy alcohol use, uncontrolled hypertension, and concomitant therapy with antiplatelet agents, NSAIDs, or paracetamol) and in the context of integrated AF care^{14,15} thus emerges as a potentially effective intervention to reduce bleeding risk in anticoagulated patients with AF.

Modifiable Bleeding Risk Factors in Anticoagulated Patients With AF

The presence of 1 or more of the 3 independent modifiable bleeding risk factors identified in this analysis approximately doubled the risk of major bleeding (Figure 4A); the modeling analysis showed additive effects with an increasing number of risk factors (Figure 4B). Thirty-nine percent of major bleeding events occurred in patients with at least 1 modifiable risk factor, suggesting that it may have been possible to reduce the risk of bleeding in a large proportion of the study population. An additional benefit of a reduced risk of bleeding is a potentially improved treatment adherence and persistence, which could lead to preventing thromboembolic events more effectively. Furthermore, reducing life-threatening bleeding events may be an important factor in reducing the risk of overall mortality in patients with AF receiving NOACs.

Concomitant therapy with antiplatelet drugs or NSAIDs increased bleeding risk in our study, confirming observations

made by others.^{6,8} NSAIDs reduce gastric protection and inhibit cyclooxygenase in platelets.¹⁶ The mechanism of action of paracetamol is less clear, but it is thought to involve the inhibition of cyclooxygenase and may also reduce gastric protection, although it is generally considered to be a safer alternative to NSAIDs in patients at an increased risk of bleeding.¹⁷ In XANTUS, there was no difference in bleeding risk in patients on paracetamol compared with those on NSAIDs. The increased risk of bleeding associated with paracetamol use may be surprising, but it is consistent with another recent analysis.¹⁸ It was not possible to determine conclusively whether this resulted directly from the use of paracetamol or another associated factor. Paracetamol use did not correlate with any other risk factors included in the analysis, but it is possible that the association could have resulted from the preferential prescription of paracetamol to patients who were already at an increased risk of bleeding.¹⁷ Overall, these results underpin the need to avoid antiplatelet or NSAID exposure in anticoagulated patients with AF,³ which are still commonly coprescribed.¹⁹

Additional analyses demonstrated that there were no differences in bleeding risk when antiplatelet agents, NSAIDs, and paracetamol were analyzed separately (Table S9), suggesting that the bleeding risk in patients receiving antiplatelet agents, which are usually taken chronically, and paracetamol/NSAIDs, which are normally taken on an as-needed, short-term basis, are similar. One possible explanation for this is that chronic pain management in elderly patients with AF (eg, due to arthritis or arthrosis) can result in regular use of paracetamol/NSAIDs. It should be noted that cessation of antiplatelet therapy to reduce the risk of bleeding may not be clinically indicated in all patients




Figure 4. Analysis of bleeding risk in patients with 0 or ≥ 1 modifiable bleeding risk factors. **A**, Kaplan-Meier curve of bleeding events in patients with 0 or ≥ 1 modifiable risk factors for bleeding. Patients with ≥ 1 modifiable risk factor (heavy alcohol use, uncontrolled hypertension, and concomitant therapy with antiplatelet agents, NSAIDs, or paracetamol) were twice as likely to experience a bleeding event compared with patients without modifiable risk factors. **B**, Model-predicted probabilities of bleeding events in patients with an average profile with respect to all risk factors (yellow), average with respect to all nonmodifiable risk factors and no (purple), 1 (green), 2 (red), or all 3 (blue) modifiable risk factors. Predicted probabilities shown at the end of each projection are for day 360. NSAID indicates nonsteroidal anti-inflammatory drug.

with AF, such as those with a recent acute coronary syndrome or recent elective percutaneous coronary intervention, for whom guidelines suggest concomitant antiplatelet and anticoagulation therapy for a limited 6- to 12-month time period.³

Uncontrolled hypertension is an independent risk factor for intracranial hemorrhage in anticoagulated⁵⁻⁷ and nonanticoagulated²⁰⁻²² patients, consistent with our analysis. Elevated pulse pressure and intravascular pressure driving chronic

Table 4. Attributable Bleeding Risk for Modifiable Risk Factors in XANTUS

Risk Factors	Partial PAR (95% CI)
Uncontrolled hypertension	0.025 (−0.019 to 0.069)
Heavy alcohol use	0.017 (−0.008 to 0.042)
Concomitant antiplatelets, NSAIDs, or paracetamol use	0.126 (0.008 to 0.242)
Uncontrolled hypertension and heavy alcohol use	0.042 (−0.020 to 0.104)
Uncontrolled hypertension and concomitant antiplatelets, NSAIDs, or paracetamol use	0.149 (0.004 to 0.289)
Heavy alcohol use and concomitant antiplatelets, NSAIDs, or paracetamol use	0.140 (0.014 to 0.262)
Uncontrolled hypertension and heavy alcohol use and concomitant antiplatelets, NSAIDs, or paracetamol use	0.163 (0.009 to 0.310)

The PAR describes the maximum proportion of major bleeding events that could theoretically be prevented if a specific risk factor and any associated pathologies were to be completely eliminated/reversed from a target population. The partial PAR is of interest where there is more than 1 risk factor of interest and when the set of risk factors includes modifiable and nonmodifiable risk factors. NSAID indicates nonsteroidal anti-inflammatory drug; PAR, population-attributable risk; XANTUS, Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation.

arterial vessel damage and precipitating acute rupture of vulnerable vessels are potential explanations for this association. In view of the additional benefits of controlling hypertension for stroke prevention,²⁰ optimal control of blood pressure should be a priority in anticoagulated patients with AF at risk of stroke.

The link between heavy alcohol consumption and bleeding is less well understood. Gastritis, esophagitis or liver dysfunction, and alcohol-induced inhibition of platelets^{23,24} could be responsible for this effect, in addition to the potentially increased chance of overdosing.

Comparison to Published Bleeding Risk Scores

Concomitant antiplatelet therapy is a component of the HAS-BLED and ORBIT scores; heavy alcohol use is included in HAS-BLED and HEMORR₂HAGES; and hypertension or uncontrolled hypertension are included in the ATRIA, HAS-BLED, and HEMORR₂HAGES scores. These scores were developed and validated in patients treated with vitamin K antagonists or in randomized trials evaluating NOAC therapy (AMADEUS [Evaluating the Use of SR34006 Compared to Warfarin or Acenocoumarol in Patients With Atrial Fibrillation], ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], and RE-LY [Randomized Evaluation of Long Term Anticoagulant Therapy]).^{5–9} In addition, the HAS-

BLED, ATRIA, and ORBIT scores have been compared using registry data on patients receiving NOACs and were found to have modest predictive value.²⁵ Our analysis confirmed these bleeding risk factors in an unselected cohort of patients treated with rivaroxaban in routine clinical practice, and the predictive discrimination of independent risk factors in our analysis was compared with ORBIT and HAS-BLED scores using Harrell's C analysis. As well as the 3 modifiable bleeding risk factors, 3 additional, nonmodifiable bleeding risk factors were identified (age, vascular disease, and heart failure).³ Age is a component of the ATRIA, HAS-BLED, HEMORR₂HAGES, and ORBIT bleeding risk scores. Vascular disease is not included in these scores and emerges as a novel bleeding risk factor in this analysis. The finding that heart failure is a risk factor for major bleeding in the XANTUS population is in accordance with another large retrospective study of unselected patients with AF treated with rivaroxaban in routine clinical practice.²⁶ All 3 are recognized stroke risk factors and part of the CHA₂DS₂-VASc score. Although potentially useful to identify patients who are at high risk of stroke and bleeding, these factors will not inform the decision for anticoagulation.^{3,4,19}

Major bleeding events were found in ≈2% of patients per year of treatment in this analysis, which is within the range of the rates of major bleeding observed in the phase III NOAC trials.^{27–30} The bleeding rate appears acceptable compared with the stroke risk in similar patients without anticoagulation,^{3,31} but this also underpins the need to reduce bleeding risk further in patients with AF receiving NOAC therapy.

Several additional risk factors for bleeding in anticoagulated patients with AF have been proposed,^{5–9} such as anemia, chronic kidney disease, impaired liver function, history of major bleeding, or previous stroke. No association between these risk factors and major bleeding was found in XANTUS, suggesting these are less relevant in patients treated with rivaroxaban.

Limitations

Enrollment into XANTUS was based on voluntary participation by centers and patients, which may have created patient or physician selection bias. Predefined criteria for events and central adjudication are means to ensure internal validity of the results, but replication in independent cohorts is warranted. Several biomarkers are associated with bleeding events in patients on anticoagulation treatment,^{7,9} but biomarkers were not recorded in XANTUS and, therefore, their effect on bleeding cannot be measured. Patient risk factors for bleeding events, except for CrCl, weight, and concomitant medications, were based on patient characteristics recorded at the screening visit before enrollment into the study; potential changes in patient risk factors (eg, development of hypertension or changes in alcohol consumption) over the duration of the study were not

considered. Additionally, patient-reported measures were used to estimate alcohol consumption; it is possible that some patients did not estimate their consumption accurately. Some heavy drinkers may have been included in the missing data group and therefore excluded from the analysis. Moreover, because of the noninterventional study design, a large proportion (39%) of patients had missing data and were excluded from the multivariate model selection procedure, which may limit the validity of the data set; however, an additional sensitivity analysis, imputing missing CrCl values (the most frequent source of missing data), showed consistent outcomes in the multivariable model. Additionally, because this analysis aimed to identify a simple model of risk factors, potential interactions between risk factors were not considered in the model selection. Nonetheless, interactions between age and modifiable risk factors, which were assessed by adding these variables individually to the final model, were not significant. The study only included patients receiving rivaroxaban and it is therefore unclear whether the findings also apply to other NOACs. Lastly, the potential impact of modifying bleeding risk factors to reduce bleeding risk assumes complete elimination and reversal of any pathological changes associated with said risk factor (eg, liver disease caused by heavy alcohol consumption or peptic ulcers causally associated with use of antiplatelet agents/NSAIDs); therefore, this represents a maximal theoretical benefit and would ideally be confirmed in a controlled trial comparing interventions to reduce modifiable bleeding risk factors with usual care. Without such data, it seems prudent to control blood pressure, to avoid heavy alcohol consumption, and reduce exposure to antiplatelets, NSAIDs, and paracetamol (unless clinically indicated) to minimize bleeding events in patients with AF anticoagulated with rivaroxaban.

Conclusions

This analysis identified 3 modifiable factors that increase bleeding risk in patients receiving NOAC therapy with rivaroxaban; elimination or reduction of these risk factors may reduce major bleeding events in anticoagulated patients with AF.

Acknowledgments

The XANTUS steering committee thanks all patients, caregivers, and families who participated in the study as well as the XANTUS investigators and associated teams. The authors would like to acknowledge Silvia Kuhls from Bayer AG, Germany for providing support with the statistical analyses and Carole Mongin-Bulewski for editorial support in preparing the manuscript, with funding from Bayer AG and Janssen Scientific Affairs, LLC. The authors confirm that this study complies with the Declaration of Helsinki and that the locally appointed ethics committees approved the research protocols. Informed consent has been obtained from all patients.

Sources of Funding

This work was supported by Bayer AG (Leverkusen, Germany) and Janssen Research & Development, LLC (Raritan, NJ).

Disclosures

Kirchhof has received research support from the European Union, the British Heart Foundation (London, UK), the Leducq Foundation (Paris, France), the German Centre for Cardiovascular Research (DZHK, Berlin, Germany), and from several drug and device companies active in atrial fibrillation (significant); he has also received honoraria from several such companies, including Bayer, Boehringer Ingelheim, Pfizer/Bristol-Myers Squibb, and Daiichi Sankyo (modest). He is listed as an inventor on 2 pending patents held by the University of Birmingham. Haas has served as a consultant for Aspen, Bayer, Bristol-Myers Squibb, Daiichi Sankyo, Pfizer, and Sanofi (modest). Amarenco has served as a consultant for Bayer (significant), Bristol-Myers Squibb (modest), Pfizer (modest), Boehringer Ingelheim (modest), Daiichi Sankyo (modest), AstraZeneca (significant), Sanofi (modest), Boston Scientific (modest), Edwards (modest), Lundbeck (modest), Merck (modest), and Kowa Pharmaceutical (modest). Hess and van Eickels are employees of Bayer AG (significant). Lambelet is an employee of Chrestos Concept, which received funding for this analysis from Bayer AG (modest). Turpie has been a consultant for Bayer, Janssen Pharmaceutical Research & Development LLC, Astellas, Portola, and Takeda (significant). Camm has received institutional research grants and personal fees as an advisor or speaker from Bayer (significant), Boehringer Ingelheim (modest), Pfizer/Bristol-Myers Squibb (modest), and Daiichi Sankyo (modest).

References

1. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, Camm AJ, Weitz JI, Lewis BS, Parkhomenko A, Yamashita T, Antman EM. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. *Lancet*. 2014;383:955–962.
2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. *Ann Intern Med*. 2007;146:857–867.
3. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Devereux S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorennek B, Guenoun M, Hohnloser SH, Kolh P, Lip GYH, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalaki P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. *Eur Heart J*. 2016;37:2893–2962.
4. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, Conti JB, Ellnor PT, Ezekowitz MD, Field ME, Murray KT, Sacco RL, Stevenson WG, Tchou PJ, Tracy CM, Yancy CW; ACC AHA Task Force Members. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. *Circulation*. 2014;130:2071–2104.

5. Fang MC, Go AS, Chang Y, Borowsky LH, Pomernacki NK, Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: the ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation) Study. *J Am Coll Cardiol*. 2011;58:395–401.
6. Pisters R, Lane DA, Nieuwlaet R, de Vos CB, Crijns HJ, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. *Chest*. 2010;138:1093–1100.
7. Gage BF, Yan Y, Milligan PE, Waterman AD, Culverhouse R, Rich MW, Radford MJ. Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). *Am Heart J*. 2006;151:713–719.
8. O'Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ, Piccini JP, Peterson ED. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. *Eur Heart J*. 2015;36:3258–3264.
9. Hijazi Z, Oldgren J, Lindback J, Alexander JH, Connolly SJ, Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S, Granger CB, Wallentin L; ARISTOTLE and RE-LY Investigators. The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. *Lancet*. 2016;387:2302–2311.
10. Camm AJ, Amarencio P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AGG. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. *Eur Heart J*. 2016;37:1145–1153.
11. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. *Stat Med*. 1996;15:361–387.
12. Sauerbrei W. The use of resampling methods to simplify regression models in medical statistics. *J R Stat Soc Ser C Appl Stat*. 1999;48:313–329.
13. Spiegelman D, Hertzmark E, Wand HC. Point and interval estimates of partial population attributable risks in cohort studies: examples and software. *Cancer Causes Control*. 2007;18:571–579.
14. Hendriks JM, de Wit R, Crijns HJ, Vrijhoef HJ, Prins MH, Pisters R, Pison LA, Blaauw Y, Tieleman RG. Nurse-led care vs. usual care for patients with atrial fibrillation: results of a randomized trial of integrated chronic care vs. routine clinical care in ambulatory patients with atrial fibrillation. *Eur Heart J*. 2012;33:2692–2699.
15. Kirchhof P. The future of atrial fibrillation management: integrated care and stratified therapy. *Lancet*. 2017;390:1873–1887.
16. Wongrakpanich S, Wongrakpanich A, Melhado K, Rangaswami J. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. *Aging Dis*. 2018;9:143–150.
17. McCrae JC, Morrison EE, MacIntyre IM, Dear JW, Webb DJ. Long-term adverse effects of paracetamol—a review. *Br J Clin Pharmacol*. 2018;84:2218–2230.
18. Gonzalez-Valcarcel J, Sissani L, Labreuche J, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Steg PG, Vicaute E, Amarencio P; PERFORM Investigators. Paracetamol, ibuprofen, and recurrent major cardiovascular and major bleeding events in 19 120 patients with recent ischemic stroke. *Stroke*. 2016;47:1045–1052.
19. De Caterina R, Ammentorp B, Darius H, Le Heuzey JY, Renda G, Schilling RJ, Schliephacke T, Reimnitz PE, Schmitt J, Schober C, Zamorano JL, Kirchhof P. Frequent and possibly inappropriate use of combination therapy with an oral anticoagulant and antiplatelet agents in patients with atrial fibrillation in Europe. *Heart*. 2014;100:1625–1635.
20. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, White IR, Caulfield MJ, Deanfield JE, Smeeth L, Williams B, Hingorani A, Hemingway H. Blood pressure and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-specific associations in 1.25 million people. *Lancet*. 2014;383:1899–1911.
21. Klungel OH, Stricker BH, Paes AH, Seidell JC, Bakker A, Voko Z, Breteler MM, de Boer A. Excess stroke among hypertensive men and women attributable to undertreatment of hypertension. *Stroke*. 1999;30:1312–1318.
22. Ko MJ, Jo AJ, Park CM, Kim HJ, Kim YJ, Park DW. Level of blood pressure control and cardiovascular events: SPRINT criteria versus the 2014 hypertension recommendations. *J Am Coll Cardiol*. 2016;67:2821–2831.
23. Pellegrini N, Pareti FI, Stabile F, Brusamolino A, Simonetti P. Effects of moderate consumption of red wine on platelet aggregation and haemostatic variables in healthy volunteers. *Eur J Clin Nutr*. 1996;50:209–213.
24. Pellegrini N, Simonetti P, Brusamolino A, Bottasso B, Pareti FI. Composition of platelet phospholipids after moderate consumption of red wine in healthy volunteers. *Eur J Clin Nutr*. 1996;50:535–544.
25. Lip GYH, Skjøth F, Nielsen PB, Kjældgaard JN, Larsen TB. The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants. *Am J Med*. 2018;131:574.e513–574.e527.
26. Tamayo S, Peacock FW, Patel M, Sicignano N, Hopf KP, Fields LE, Sarich T, Wu S, Yannicelli D, Yuan Z. Characterizing major bleeding in patients with nonvalvular atrial fibrillation: a pharmacovigilance study of 27 467 patients taking rivaroxaban. *Clin Cardiol*. 2015;38:63–68.
27. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. *N Engl J Med*. 2011;365:883–891.
28. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Gerdal M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FWA, Zhu J, Wallentin L; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2011;365:981–992.
29. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Spinar J, Ruzylo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2013;369:2093–2104.
30. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med*. 2009;361:1139–1151.
31. Hart RG, Pearce LA, Aguilar MI. Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation. *Ann Intern Med*. 2007;147:590–592.

SUPPLEMENTAL MATERIAL

Appendix

XANTUS Investigators

Germany: A. Al-Zoebe, N. Schön, O. Scheuermann, T. Schröder, G. Weyers, M. Salefsky, K.-F. Appel, K. Jocham, W. Rieker, A. Schnabel, R. Bosch, J. Dahm, J. Brachmann, C. Schwencke, S. Ragab, W. Jung, G. Stenzel, M. Antz, M. Grebe, H. Diedrichs, A. Mügge, M. Gabelmann, U. Hoffmann, A. Krummenerl, M. Leicht, J. Merke, N. Proskynitopoulos, F. Richard, U. Schulze, J. Taggeselle, M. Conze, U. Frees, M. Leschke, H. Heuer, C. Piper, H.-E. Sarnighausen, A. Krämer, G. Hübner, P. Krings, C. Stellbrink, C. Bauknecht, G. Nickenig, B. Hügl, R. Steinhard, R. Hambrecht, M. Kroll, D. Gulba, R. Stöhring, L. Drude, A. Stadelmann, P. Schwimmbeck, C. Axthelm, F. Pröpper; **United Kingdom:** C. Harinath, C. Kausik, J. Finlayson, A. Dixit, F. Osman, P. Davey, D. Mangion, P. Nair, H. Kadr, P. Sharma, R. Arya, P. Kirchhof; **France:** P. Amarenco, M. Pillot, S. Ansaldi, J.-P. Bellefleur, K. Bouchlaghem, P. Chemin, P. Chevalier, C. Chisseray Pramotton, R. Chokron, A. Ciaus, D. Coisne, S. Combes, Y. Cottin, R. Crespy, A. Dabboura, P. Dematteo, M. Elbaz, J.-L. Farges, J.-M. Fauchaux, L. Fauchier, E. Foltzer, P.-Y. Fournier, J. Gauthier, B. Grivet, B. Guillon, R. Khalvadjian, B. Koujan, J.-N. Labeque, J.-P. Labbe, J.-L. Long, M. Loubet, P. Samama, M. Martelet, S. Mielot, J.-P. Neau, V. Probst, A. Rifai, Y. Samson, B. Truong Minh Ky, F. Viader, A. Corbin, P. Dafaye, P. Lang, A. Dompnier, A. Hagege, N. Lellouche, S. Destrac, N. Nighoghossian, S. Guerard, J. M. Davy, J. F. Aupetit, A. Durand Dubief, A. Gacem, M. Zylberberg, E. Fournier, S. Kownator, W. Amara, J. P. Elkaim, E. Ferrari, G. Napporn, P. F. Winum, E. Aliot, M. Sarov-Rivière; **Poland:** Z. Kornacewicz-Jach, E. Zinka, M. Nartowicz-Słoniewska, B. Mocarska-Górna, G. Latocha-Korecka, A. Stasiewski, J. Tyszkiewicz, T. Lepich, R. Kluba, W. Piotrowski, B. Mikłaszewicz, M. Pawłowska, S. Mazur; **Canada:** G. Houde, F. Grondin, B. Craig, C. Lai, S. Lam, A. Kucktaruk, G. Sabe-Affaki, M. Miller, L. Hill, A. Kelly, S. Fikry, F. St-Maurice, P. Filteau, A. Fréchette, M. Csanadi, M. Mason, G. Chouinard, R. Gendreau; **Belgium:** P. Melon, L. De Wolf, H. Heidbüchel, L. Janssens, C. Scavée, E. Hoffer, J. Leroy,

T. Boussy; **Netherlands:** A. Elvan, W. Hermans, H. Suryapranata, M. van Eck, P. Van Haelst, J. Meeder, P. Hoogslag, H. Kragten, R. Tukkie, M. Hemels, L. Van Wijk, P. Nierop, W. Ten Holt, P. Zwart, A. Bakx, A. Kuijper, R. de Nooijer, R. Van der Heijden, J. ten Berg, H. Beyerbacht, J. L. Brouwer, B. Van den Berg, F. Den Hartog; **Sweden:** C. Blomström Lundqvist, A.-C. Laska, C. Rorsman, E. Moor, C.-J. Lindholm, S. Lind, J. Teichert, T. Grähs, L. Falk, S. Bandh; **Denmark:** H. Nielsen, S. Riahi, S. Pehrson, E. Zeuten, G. Jensen, G. Gislason, H. Ibsen, P. Hildebrandt; **Norway:** E. Øie, M. Kurz, P. K. Rønnevik; **Czech Republic:** O. Škoda, F. Málek, M. Souček, J. Spinar, D. Marek, R. Mikulik, P. Jansky, M. Bar, M. Barsovsky, L. Krajcova, M. Homza; **Israel:** R. Shohat Zabarski, W. Nseir, Z. Vered, U. Rosenschein; **Portugal:** J. Martinez, P. Canhão, T. Gregorio, R. Fontes Carvalho; **Austria:** H. J. Nesser, U. Hoppe, B. M. Pieske, J. R. Weber, C. Brenneis, A. Winkler, K. Huber, A. Gatterer, A. Podczek-Schweighofer, M. Gwechenberger, F. Weidinger; **Hungary:** Z. Csanadi, Z. Jarai, A. Vertes, K. Zamolyi; **Russia:** A. Tarasov, I. Baychorov, M. Kubova, M. Ryabinina, S. Matskeplishvilli, V. Sulimov, S. Kozhevnikova, E. Adonina, V. Lartseva, A. Shimkevich, A. Rychkov, N. Khorkova, O. Kolycheva, S. Zenin, O. Kononenko, E. Vlasants, M. Dereva, E. Vedeneva, E. Minasova, S. Popov, S. Usenkov, I. Kisteneva, R. Batalov, G. Spacencov, S. Kuznetsov, T. Tsybulskaya, M. Vitsenya, O. Vyborov, I. Shlyk, I. Voznyuk, A. Muhamedrahimova, A. Obrezan; **Slovakia:** M. Tvrdikova, S. Filipova, E. Roskova, J. Strbova, S. Farsky, D. Pella, I. Nedělová, F. Fazekas, J. Pacharová, Z. Lašanová, P. Hlivák, P. Spurný, V. Pokorna, M. Mora, M. Stefanik; **Ukraine:** O. Karlinska, O. Sychov, T. Grygorieva, O. Gukov, O. Romanenko, T. Petrovskyy, M. Gorbach, D. Reshotko, G. Maxym; **Slovenia:** V. Kanic, M. Marija, G. Mirjam, T. Šubic; **Ireland:** N. Mahon; **Moldova:** A. Grosu, A. Grivenco, R. Grajdieru, N. Diaconu.

Table S1. Definitions of uncontrolled hypertension, vascular disease, and heart failure.

Parameter	Definition used
Uncontrolled hypertension	Blood pressure >160/90 mm Hg
Vascular disease	Recorded according to type (peripheral artery disease, ischemic heart disease, or cerebrovascular disease), as assessed by the treating physician
Heart failure	Clinically defined using reduced left ventricular ejection fraction

Table S2. Risk factors selected after univariate analysis for inclusion in the multivariable Cox regression model.

	HR (95% CI)	P-value
Risk factors included in multivariate model based on $P < 0.1$ in univariate analysis		
Age at baseline (5-year increase)	1.31 (1.18–1.45)	<0.001
Heart failure at baseline: Yes vs No	2.42 (1.68–3.47)	<0.001
Vascular disease at baseline: Yes vs No	2.31 (1.63–3.28)	<0.001
Concomitant antiplatelet therapy, NSAIDs, or paracetamol use at any time during study: Yes vs No	1.97 (1.36–2.86)	<0.001
Rivaroxaban dose (first documented): Overall		<0.001
20 mg vs 15 mg	0.57 (0.39–0.83)	0.003
Other or missing vs 15 mg	3.16 (0.98–10.23)	0.055
History of hypertension: Yes vs No	1.80 (1.12–2.91)	0.015
Concomitant dual antiplatelet therapy at any time during study: Yes vs No	2.99 (1.22–7.32)	0.016
Hepatic insufficiency: Yes vs No	2.38 (1.05–5.40)	0.038
Alcohol consumption at baseline: Overall		0.091
Alcohol consumption at baseline: Heavy vs Abstinent or mild	3.12 (0.99–9.82)	0.052
Alcohol consumption at baseline: Medium vs Abstinent or mild	0.71 (0.35–1.46)	0.355
Risk factors included in multivariate model based on medical judgment		
Concomitant CYP3A4 or P-gp inhibitors* at any time during study (modelled as time dependent): Yes vs No	1.41 (0.93–2.13)	0.105
Renal insufficiency: First available CrCl <50 mL/min vs ≥50 mL/min	1.46 (0.92–2.33)	0.109
Uncontrolled hypertension: Yes vs No	1.64 (0.80–3.36)	0.175
Anemia or reduced hemoglobin [#] : Yes vs No	1.70 (0.75–3.85)	0.207
Prior stroke: Yes vs No	1.27 (0.80–2.02)	0.301

Sex: Male vs Female	1.18 (0.82–1.69)	0.368
First available weight: >60 kg vs ≤60 kg	0.86 (0.46–1.61)	0.644
Previous labile INR documented: Yes vs No	1.11 (0.68–1.81)	0.676

*Strong, moderate and weak inhibitors were included.

#Anemia as recorded at baseline; hemoglobin data based on first available data recorded at baseline or at any time during the study.

CI indicates confidence interval; CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; HR, hazard ratio; INR, international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein.

Table S3. Internal validation of XANTUS bleeding model using an optimism-corrected version of Harrell's C-index.

Apparent C*	Averaged optimism Estimate O[#]	Harrell's C corrected for optimism estimation[†]
0.728	0.036	0.692

*Calculation of the apparent C using all patients with backward selection of the variables.

[#]Average value from 200 bootstrap samples.

[†]Corrected for optimism estimation.

Table S4. Baseline demographics and clinical characteristics of patients with and without treatment-emergent major bleeding events or treatment-emergent death events in XANTUS.

	All patients (N=6784)	Patients with major bleeding or death (n=232)	Patients without major bleeding or death (n=6552)	P-value
Age years, mean \pm SD	71.5 \pm 9.95	76.6 \pm 10.07	71.3 \pm 9.89	<0.001
<75 years, n (%)	3975 (58.6)	90 (38.8)	3885 (59.3)	<0.001
\geq 75 years, n (%)	2809 (41.4)	142 (61.2)	2667 (40.7)	<0.001
Male, n (%)	4016 (59.2)	137 (59.1)	3879 (59.2)	0.9566
Body mass index, kg/m ² , mean \pm SD	28.3 \pm 4.98	27.6 \pm 5.68	28.4 \pm 4.95	0.0425
First available creatinine clearance, n (%)				
<80 mL/min	2961 (43.6)	145 (62.5)	2816 (43.0)	0.0049
\geq 80 mL/min	1491 (22.0)	46 (19.8)	1445 (22.1)	0.0049
Missing	2332 (34.4)	41 (17.7)	2291 (35.0)	0.0049
Hepatic insufficiency, n (%)*	137 (2.0)	12 (5.2)	125 (1.9)	0.0005
Rivaroxaban dose (first documented), n (%)				

15 mg	1410 (20.8)	82 (35.3)	1328 (20.3)	<0.0001
20 mg	5336 (78.7)	144 (62.1)	5192 (79.2)	<0.0001
Other/missing	38 (0.6)	6 (2.6)	32 (0.5)	<0.0001
Concomitant ASA or NSAIDs, n (%)	1118 (16.5)	51 (22.0)	1067 (16.3)	0.0215
Concomitant dual antiplatelets, n (%)	105 (1.5)	8 (3.4)	97 (1.5)	0.0170
Concomitant antiplatelet, NSAIDs, or paracetamol, n (%)	1363 (20.1)	72 (31.0)	1291 (19.9)	<0.0001
Concomitant CYP3A4 or P-gp inhibitors, n (%) [#]	1313 (19.4)	59 (25.4)	1254 (19.1)	0.0171
Concomitant paracetamol, n (%)	191 (2.8)	21 (9.1)	170 (2.6)	<0.0001
Active cancer, n (%)	105 (1.5)	9 (3.9)	96 (1.5)	0.0034
Prior bleeding, n (%)	49 (0.7)	3 (1.3)	46 (0.7)	0.2961
Ulcerative gastrointestinal disease, n (%)	27 (0.4)	2 (0.9)	25 (0.4)	0.2533
Uncontrolled hypertension, n (%)	275 (4.1)	10 (4.3)	265 (4.0)	0.8401
Prior stroke, n (%)	935 (13.8)	48 (20.7)	887 (13.5)	0.0019
Prior MI, n (%)	688 (10.1)	41 (17.7)	647 (9.9)	0.0001
Heart failure at baseline, n (%)	1265 (18.6)	92 (39.7)	1173 (17.9)	<0.0001
Platelet count <80 000, n (%)	39 (0.6)	2 (0.9)	37 (0.6)	0.9282

Diabetes mellitus, n (%)	1333 (19.6)	60 (25.9)	1273 (19.4)	0.0154
Vascular disease, n (%)	1685 (24.8)	91 (39.2)	1594 (24.3)	<0.0001
Heavy alcohol use, n (%)	54 (0.8)	5 (2.2)	49 (0.7)	0.0089
Anemia/reduced hemoglobin, n (%)	203 (3.0)	19 (8.2)	184 (2.8)	<0.0001
Known coagulopathy, n (%)	19 (0.3)	2 (0.9)	17 (0.3)	0.0878
Bridging therapy during interruptions, n (%)	100 (1.5)	12 (5.2)	88 (1.3)	<0.0001

The baseline demographics and clinical characteristics from patients from the XANTUS study were stratified according to the presence or absence of major bleeding or death.

*Defined as 'abnormal liver function' by the study investigator.

#Strong, moderate, and weak inhibitors were included.

ASA indicates acetylsalicylic acid; CYP3A4, cytochrome P450 3A4; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein; SD, standard deviation.

Table S5. Baseline demographics and clinical characteristics of patients included in, and excluded from, the multivariable model selection procedure.

	Patients included in multivariate model (n=4127)	Patients excluded from multivariate model because of ≥ 1 missing value (n=2657)	P-value
Age years, mean \pm SD	71.6 \pm 10.08	71.4 \pm 9.73	0.5007
<75 years, n (%)	2402 (58.2)	1573 (59.2)	0.4144
≥ 75 years, n (%)	1725 (41.8)	1084 (40.8)	
Male, n (%)*	2423 (58.7)	1593 (60.0)	0.2834
BMI, kg/m ² , mean \pm SD	28.2 \pm 4.98	28.6 \pm 4.97	0.0273
First available CrCl, n (%)	—	—	0.0098
<50 mL/min	3518 (85.2)	294 (90.5)	
≥ 50 mL/min	609 (14.8)	31 (9.5)	
Missing	0	2332	
Hepatic insufficiency, n (%)#	95 (2.3)	42 (1.6)	0.0393
Rivaroxaban dose (first documented), n (%)	—	—	<0.0001
15 mg	931 (22.6)	479 (18.0)	
20 mg	3174 (76.9)	2162 (81.4)	

Other/missing	22 (0.5)	16 (0.6)	
Concomitant ASA or NSAIDs, n (%)	707 (17.1)	411 (15.5)	0.0716
Concomitant dual antiplatelets, n (%)	66 (1.6)	39 (1.5)	0.6687
Concomitant antiplatelet, NSAIDs, or paracetamol, n (%)	872 (21.1)	491 (18.5)	0.0078
Concomitant CYP3A4 or P-gp inhibitors, n (%) [†]	855 (20.7)	458 (17.2)	0.0004
Concomitant paracetamol, n (%)	150 (3.6)	41 (1.5)	<0.0001
Active cancer, n (%)	72 (1.7)	33 (1.2)	0.1016
Prior bleeding, n (%)	31 (0.8)	18 (0.7)	0.7264
Ulcerative gastrointestinal disease, n (%)	18 (0.4)	9 (0.3)	0.5339
Uncontrolled hypertension, n (%)	149 (3.6)	126 (4.7)	0.0210
Prior stroke, n (%) [‡]	608 (14.7)	327 (12.3)	0.0049
Prior MI, n (%)	440 (10.7)	248 (9.3)	0.0770
Heart failure at baseline, n (%)	851 (20.6)	414 (15.6)	<0.0001
Platelet count, n (%)	—	—	<0.0001
<80 000	23 (0.9)	16 (4.8)	
≥80,000	2529 (99.1)	315 (95.2)	
Missing	1575	2326	

Diabetes mellitus, n (%)	856 (20.7)	477 (18.0)	0.0048
Vascular disease, n (%)	1097 (26.6)	588 (22.1)	<0.0001
Alcohol consumption, n (%)	–	–	0.5844
Abstinent or mild	3724 (90.2)	2209 (89.6)	
Medium	372 (9.0)	234 (9.5)	
Heavy	31 (0.8)	23 (0.9)	
Missing	0	191	
Anemia/reduced hemoglobin, n (%)	162 (3.9)	41 (1.5)	<0.0001
Known coagulopathy, n (%)	9 (0.2)	10 (0.4)	0.2285
Bridging therapy during interruptions, n (%)	80 (1.9)	20 (0.8)	<0.0001

% and *P*-values are based on number of patients with available data for each characteristic.

*Information missing for 3 patients excluded from the multivariate model.

#Defined as 'abnormal liver function' by the study investigator.

†Strong, moderate and weak inhibitors were included.

‡Information missing for 2 patients excluded from the multivariate model.

ASA indicates acetylsalicylic acid; BMI, body mass index; CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein; SD, standard deviation.

Table S6. Baseline demographics and clinical characteristics of patients with and without treatment emergent major bleeding in the model population (n=4127).

	Patients with major bleeding (n=105)	Patients without major bleeding (n=4022)	P-value
Age years, mean \pm SD	75.9 \pm 9.5	71.5 \pm 10.1	<0.0001
<75 years, n (%)	42 (40.0)	2360 (58.7)	0.0001
\geq 75 years, n (%)	63 (60.0)	1662 (41.3)	
Male, n (%)	64 (61.0)	2359 (58.7)	0.6365
BMI, kg/m ² , mean \pm SD	28.33 \pm 5.41	28.23 \pm 4.97	0.8544
First available CrCl, n (%)			0.0698
<50 mL/min	22 (21.0)	587 (14.6)	
\geq 50 mL/min	83 (79.0)	3435 (85.4)	
Hepatic insufficiency, n (%)*	6 (5.7)	89 (2.2)	0.0182
Rivaroxaban dose (first documented), n (%)			0.0033
15 mg	35 (33.3)	896 (22.3)	
20 mg	68 (64.8)	3106 (77.2)	
Other/missing	2 (1.9)	20 (0.5)	

Concomitant ASA or NSAIDs, n (%)	31 (29.5)	676 (16.8)	0.0006
Concomitant dual antiplatelets, n (%)	5 (4.8)	61 (1.5)	0.0089
Concomitant antiplatelet, NSAIDs, or paracetamol, n (%)	38 (36.2)	834 (20.7)	0.0001
Concomitant CYP3A4 or P-gp inhibitors, n (%) [#]	31 (29.5)	824 (20.5)	0.0241
Concomitant paracetamol, n (%)	9 (8.6)	141 (3.5)	0.0062
Active cancer, n (%)	3 (2.9)	69 (1.7)	0.3778
Prior bleeding, n (%)	1 (1.0)	30 (0.7)	0.8088
Ulcerative gastrointestinal disease, n (%)	0 (0)	18 (0.4)	0.4921
Uncontrolled hypertension, n (%)	7 (6.7)	142 (3.5)	0.0890
Prior stroke, n (%)	21 (20.0)	587 (14.6)	0.1229
Prior MI, n (%)	15 (14.3)	425 (10.6)	0.2229
Heart failure at baseline, n (%)	40 (38.1)	811 (20.2)	<0.0001
Platelet count <80 000, n (%)	2 (2.6)	21 (0.8)	0.1051
Diabetes mellitus, n (%)	28 (26.7)	828 (20.6)	0.1293
Vascular disease, n (%)	50 (47.6)	1047 (26.0)	<0.0001
Alcohol consumption, n (%)			0.0299
Abstinent or mild	95 (90.5%)	3629 (90.2)	

Medium	7 (6.7)	365 (9.1%)	
Heavy	3 (2.9)	28 (0.7)	
Anemia/reduced hemoglobin, n (%)	6 (5.7)	156 (3.9)	0.3390
Known coagulopathy, n (%)	1 (1.0)	8 (0.2)	0.1023
Bridging therapy during interruptions, n (%)	11 (10.5)	69 (1.7)	<0.0001

*Defined as 'abnormal liver function' by the study investigator.

#Strong, moderate and weak inhibitors were included.

ASA indicates acetylsalicylic acid; BMI, body mass index; CrCl, creatinine clearance; CYP3A4, cytochrome P450 3A4; MI, myocardial infarction; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein; SD, standard deviation.

Table S7. Independent factors associated with major bleeding or death in the XANTUS population (N=6784).

Risk factors	HR	95% CI	P-value
Heart failure at baseline: Yes vs No	2.27	(1.64–3.16)	<0.001
Age (5-year increase)	1.21	(1.10–1.33)	<0.001
Concomitant antiplatelets, NSAIDs, or paracetamol use: Yes vs No	1.76	(1.26–2.47)	<0.001
Rivaroxaban dose (first documented): Overall			0.003
Rivaroxaban dose (first documented): 20 mg vs 15 mg	0.70	(0.49–0.99)	0.043
Rivaroxaban dose (first documented): Other or missing vs 15 mg	3.35	(1.21–9.28)	0.020
Vascular disease: Yes vs No	1.56	(1.13–2.16)	0.007
Hepatic insufficiency: Yes vs No*	2.27	(1.21–4.27)	0.011
Anemia or reduced hemoglobin use: Yes vs No	1.58	(0.92–2.70)	0.095

Multivariable Cox proportional hazard model of time-dependent risk factors for treatment-emergent adjudicated major bleeding or treatment-emergent adjudicated death. This analysis was performed as a sensitivity analysis for the factors predicting major bleeding. All factors with the exception of heavy alcohol use and uncontrolled hypertension were confirmed in the sensitivity analysis. Hepatic insufficiency, a common consequence of long-term heavy alcohol abuse, was associated with major bleeding or death.

*Defined as 'abnormal liver function' by the study investigator.

CI indicates confidence interval; HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory drug.

Table S8. Alcohol equivalence.

Alcohol consumption category	Gram alcohol per day	Country	Glasses per day		
			Beer (5% alcohol by volume)	Wine (12% alcohol by volume)	Spirits (40% alcohol by volume)
Abstinent	0	All countries	0	0	0
Mild	<40	Germany, France, Italy, Japan	<4 glasses at 0.2 L/glass	<2 glasses at 0.2 L/glass	<5 glasses at 2 cL/glass
		United Kingdom	<1.5 pints	<3 glasses at 125 mL/glass	<4 measures at 25 mL/glass
		Russia	<2.5 glasses at 0.33 L/glass	–	<2 glasses at 50 mL/glass
		North America	<2 cans at 12 fluid ounces/can	<2 glasses at 5 fluid ounces/glass	<2 glasses at 1.5 fluid ounces/glass
Moderate	40–80	Germany, France, Italy, Japan	4–8 glasses at 0.2 L/glass	2–4 glasses at 0.2 L/glass	5–10 glasses at 2 cL/glass
		United Kingdom	1.5–3 pints	3–6 glasses at 125 mL/glass	4–8 measures at 25 mL/glass

Heavy	>80	Russia	2.5–5 glasses at 0.33 L/glass	–	2–4 glasses at 50 mL/glass
		North America	2–4 cans at 12 fluid ounces/can	2–5 glasses at 5 fluid ounces/glass	2–4 glasses at 1.5 fluid ounces/glass
		Germany, France, Italy, Japan	>8 glasses at 0.2 L/glass	>4 glasses at 0.2 L/glass	>10 glasses at 2 cL/glass
		United Kingdom	>3 pints	>6 glasses at 125 mL/glass	>8 measures at 25 mL/glass
		Russia	>5 glasses at 0.33 L/glass	–	>4 glasses at 50 mL/glass
		North America	>4 cans at 12 fluid ounces/can	>5 glasses at 5 fluid ounces/glass	>4 glasses at 1.5 fluid ounces/glass

The categories of alcohol consumption (abstinent, mild, moderate, and heavy) were defined by the total daily alcohol content (in grams) consumed by the individual. The categories were created so that subgroup analyses could be performed.

The definitions used are provided in the Table S5. For example: if an individual consumed beer at <800 mL/day (<40 g alcohol/day), he/she was classified as a mild alcohol consumer. However, if the individual consumed 500 mL/day of beer and 250 mL of wine, he/she was classified as a moderate alcohol consumer (25 g alcohol/day of beer + 30 g alcohol/day of wine = 55 g alcohol/day).

If the country where the trial was being conducted is not listed in the table (eg, Sweden), the closest country could be used. For example, investigators in Sweden could use the ‘Germany, France, Italy, Japan’ category.

Table S9. Antithrombotic treatment as risk factors for major bleeding.

Risk factors	HR*	95% CI	P-value
Concomitant antiplatelet, NSAID or paracetamol	1.97	1.36–2.86	<0.001
Concomitant antiplatelet	1.69	1.13–2.55	0.012
Concomitant NSAID or paracetamol	2.19	1.23–3.88	0.007
Concomitant paracetamol	2.64	1.34–5.19	0.005
Concomitant antiplatelet or NSAID	1.77	1.20–2.61	0.004
Concomitant NSAID	1.73	0.76–3.92	0.191

*Shown for the comparison of concomitant antithrombotic therapy yes vs no in separate univariate Cox proportional hazard models.

CI indicates confidence interval; HR, hazard ratio; NSAID, nonsteroidal anti-inflammatory drug.

Table S10. Independent factors associated with major bleeding in the XANTUS population in a sensitivity analysis with imputation of missing CrCl values (n=5896).

Risk factors	HR	95% CI	P-value
Age (5-year increase)	1.27	1.14–1.41	<0.001
Heart failure at baseline: Yes vs No	2.08	1.42–3.07	<0.001
Vascular disease: Yes vs No	1.94	1.33–2.84	<0.001
Concomitant antiplatelets, NSAIDs, or paracetamol use: Yes vs No	1.95	1.32–2.88	<0.001
Alcohol consumption at baseline: Overall			0.090
Alcohol consumption at baseline: Heavy vs Abstinent or mild	3.58	1.13–11.34	0.030
Alcohol consumption at baseline: Medium vs Abstinent or mild	0.91	0.42–1.96	0.806

A backwards selection was done using a *P*-value of 0.1 for variables to stay in the model.

Candidate risk factors were used as for the primary analysis shown in Table S2.

Patients with missing CrCl and CrCl ≥ 50 mL/min were grouped together because a comparison of baseline characteristics and event rates between patients with and without CrCl showed that those with missing data were generally healthier than those with available data, i.e. they have fewer co-morbidities (e.g. hypertension, prior stroke, heart failure and diabetes) and were less likely to have a stroke, bleeding event or die.

CI indicates confidence interval; CrCl, creatinine clearance; HR, hazard ratio; INR, international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug; P-gp, P-glycoprotein.

Table S11. Major bleeding or death in the XANTUS population stratified by the number of modifiable bleeding risk factors.

Number of modifiable risk factors	Overall n (%)	Patients with major bleeding events or death* n (%)	Incidence proportion % (95% CI)	Incidence rate Events per 100 years (95% CI)
0	5150 (75.9)	148 (2.9)	2.87 (2.43–3.37)	3.15 (2.66–3.70)
1	1577 (23.2)	81 (5.1)	5.14 (4.10–6.34)	6.00 (4.77–7.46)
≥2	57 (0.8)	3 (5.3)	5.26 (1.10–14.62)	6.22 (1.28–18.18)

Number of patients and major bleeding events or death from the XANTUS study were stratified according to the number of modifiable risk factors.

*Treatment-emergent adjudicated.

#Only one patient had three modifiable bleeding risk factors and did not experience a bleeding event.

CI indicates confidence interval.

Table S12. Assessment of interactions between age and modifiable risk factors.

Modifiable risk factor	Age <75 years		Age ≥75 years		<i>P</i> -value (interaction)*
	Patients with major bleeding n/N (%)	Incidence rate Events per 100 patient-years (95% CI)	Patients with major bleeding n/N (%)	Incidence rate Events per 100 patient-years (95% CI)	
Concomitant antiplatelet, NSAID or paracetamol					0.997
Yes	17/757 (2.2)	2.59 (1.51–4.15)	24/606 (4.0)	4.75 (3.04–7.07)	
No	35/3218 (1.1)	1.18 (0.82–1.65)	52/2203 (2.4)	2.63 (1.97–3.45)	
Alcohol consumption					0.746
Abstinent or mild	42/3371 (1.2)	1.37 (0.99–1.85)	67/2562 (2.6)	2.97 (2.30–3.77)	
Medium	4/448 (0.9)	0.99 (0.27–2.54)	4/158 (2.5)	2.81 (0.77–7.20)	
Heavy	2/42 (4.8)	5.74 (0.70–20.75)	1/12 (8.3)	8.38 (0.21–46.68)	
Uncontrolled hypertension					0.171
Yes	4/159 (2.5)	2.92 (0.80–7.48)	4/116 (3.4)	3.96 (1.08–10.14)	
No	48/3816 (1.3)	1.38 (1.02–1.83)	72 /2693(2.7)	3.03 (2.37–3.81)	

*The interaction *P*-values were calculated using the model including age (continuous), heart failure, vascular disease, concomitant antiplatelet therapy, NSAID or paracetamol, alcohol consumption, uncontrolled hypertension and one interaction at a time.

CI indicates confidence interval; NSAID, nonsteroidal anti-inflammatory drug.

Table S13. Major bleeding in the XANTUS population stratified by HAS-BLED and ORBIT bleeding risk scores and validation of the XANTUS bleeding score using Harrell's C-index.

Score category	Overall n (%)	Patients with major bleeding* n (%)	Incidence proportion, % (95% CI)	Incidence rate Events per 100 years (95% CI)	Harrell's C of scores (individual score points) (95% CI)	Harrell's C of scores (categorizations) (95% CI)
HAS-BLED score[†]					0.59 (0.55–0.64)	0.56 (0.52–0.61)
Low (0)	318 (4.7)	1 (0.3)	0.31 (0.01–1.74)	0.36 (0.01–2.03)		
Medium (1–2)	4593 (67.7)	78 (1.7)	1.70 (1.34–2.11)	1.89 (1.49–2.35)		
High (≥3)	1854 (27.3)	48 (2.6)	2.59 (1.91–3.42)	2.88 (2.12–3.82)		
ORBIT score[‡]					0.62 (0.54–0.69)	0.59 (0.52–0.66)
Low (0–2)	1192 (17.6)	27 (2.3)	2.27 (1.50–3.28)	2.61 (1.72–3.80)		
Medium (3)	270 (4.0)	13 (4.8)	4.81 (2.59–8.09)	5.89 (3.13–10.07)		
High (4–7)	240 (3.5)	11 (4.6)	4.58 (2.31–8.05)	5.54 (2.76–9.91)		

Number of patients and major bleeding events from the XANTUS study were stratified by HAS-BLED and ORBIT bleeding risk scores. The score for a patient is unknown if the information on one of the components of the score is missing.


*Treatment emergent adjudicated.

[†]Risk factors: **H**ypertension (uncontrolled), **A**bnormal renal and liver function (one point each), **S**troke, **B**leeding (history or predisposition (anemia)), **L**abile INRs, **E**lderly (>65 years), **D**rugs or alcohol (one point for antiplatelet agents, other anticoagulants or NSAIDs; one point for alcohol excess).

‡Risk factors: Older age (75 years or older), Reduced hemoglobin (<13 mg/dL in men and <12 mg/dL in women), hematocrit (<40% in men and <36% in women) or history of anemia, Bleeding history, Insufficient kidney function (eGFR <60 mg/dL/1.73 m²), Treatment with antiplatelets.

CI indicates confidence interval; eGFR, estimated glomerular filtration rate; INR, international normalized ratio; NSAID, nonsteroidal anti-inflammatory drug.

Figure S1. Graphical assessment of the proportional hazards assumption of the risk factors.



A, age; **B**, congestive heart failure; **C**, vascular disease; **D**, uncontrolled hypertension; **E**, alcohol usage; and **F**, NSAID or paracetamol usage.

NSAID indicates nonsteroidal anti-inflammatory drug.

Figure S2. Assessment of linearity for age – smoothed plot of Martingale residuals.





Figure S3. Calibration plot assessing correlation between actual and predicted probabilities in the final multivariate model.



d indicates number of patients with an event; N, number of patients.